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ABSTRACT
Respiratory syncytial virus (RSV) is a signiﬁcant respiratory pathogen but no vaccine is available. RSV
infections present 2 major, unique problems. First, humans can experience repeated infections caused by
the same virus sero-group indicating that protective memory responses to RSV infection are defective.
Second, most people have been infected with RSV by age 5. Immune responses to these infections,
while poorly protective, could impact the effectiveness of a vaccine. The goal of this study was to assess
the generation of protective immune responses in mice previously infected with RSV by virus-like particle
(VLP) vaccine candidates containing a stabilized pre-fusion form of the RSV F protein or a stabilized post-
fusion F protein. We report that a single immunization of RSV-experienced animals with a stabilized pre-
fusion F protein VLP stimulated high titers of neutralizing antibody while a single injection of a post-fusion
F protein VLP or a second RSV infection only weakly stimulated neutralizing antibody titers. These results
suggest that prior RSV infection can induce neutralizing antibody memory responses, which can be
activated by pre-F protein VLPs but not by post-F protein VLPs or a subsequent infection. Thus the F
protein conformation has a major impact on enhancing production of neutralizing antibodies in RSV-
experienced animals. Furthermore, although both VLPs contained the same RSV G protein, the pre-F VLP
stimulated signiﬁcantly higher titers of total anti-G protein IgG than the post-F VLP in both na€ıve and RSV-
experienced animals. Thus the F protein conformation also inﬂuences anti-G protein responses.
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Introduction
Respiratory syncytial virus (RSV) is a signiﬁcant human patho-
gen most severely affecting infants, young children, and the
elderly. The virus is the single most important cause of acute
viral respiratory disease in infants and young children fre-
quently resulting in hospitalization in the US and in signiﬁcant
mortality rates in developing countries.1 RSV infection also
substantially impacts elderly and immunocompromised popu-
lations,2-5 and results in considerable morbidity in normal adult
populations.6 Despite the signiﬁcance of RSV disease, there are
no vaccines available although numerous candidates have been
characterized in preclinical and clinical studies spanning 5 dec-
ades. This failure is due in large part to a lack of understanding
of some fundamental issues related to immune responses to
RSV.
A signiﬁcant problem has been a lack of understanding of
RSV antigens required for generation of protective, neutralizing
anti-RSV antibodies. Many vaccine candidates, while stimulat-
ing antibody responses in experimental animals or humans,
have failed to induce protection in human trials (reviewed in7-9).
One reason for this failure is that many candidates did not con-
tain the appropriate form of the F protein. Like other paramyxo-
virus F proteins, the RSV F protein is folded into a metastable
pre-fusion conformation and upon fusion activation refolds into
a structurally very different post-fusion conformation.10-14 The
pre-fusion form of F protein is most effective in stimulating opti-
mally neutralizing antibodies.14,15 Furthermore, McLellan, et al15
have shown that a soluble form of pre-fusion F protein, stabi-
lized by mutation (DS-Cav1 mutant F protein), stimulated signif-
icantly higher neutralizing antibody titers in mice than those
stimulated by post-fusion forms. What has not been appreciated
until recently is that the pre-fusion form of the RSV F protein is
unusually unstable and that many previous vaccine candidates
contained primarily the post-fusion form.
Another signiﬁcant problem for vaccine development has
been a lack of understanding of requirements for the generation
of long-lived and memory responses to RSV. One hallmark of
RSV infection is that humans can experience repeated infec-
tions caused by the same virus sero-group over several years or
even within the same season6,7,16 indicating that memory
responses to RSV infection are defective.16
A further complication for vaccine development is that most
of the human population has experienced RSV infection by
2–5 y of age.17 While pre-existing immunity is poorly
protective, it could well impact the effectiveness of a vaccine.
Thus a successful vaccine candidate must stimulate high titers
of neutralizing antibody in the face of any preexisting immu-
nity, a topic that has not been widely addressed. Results in
model animal systems using na€ıve animals may not directly
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bear on human responses, which will virtually always be in the
context of previous infection.
We have developed novel virus-like particle (VLP) vaccine
candidates for RSV.18,19 Because of their particulate nature and
their presentation of antigens in a repetitive array, VLPs do not
need the addition of adjuvant for potent immune responses, in
contrast to soluble proteins.20 Because production of VLPs
does not require viral replication, different conformational
forms of antigens, such as a stabilized pre-fusion F protein or a
stabilized post fusion F protein, can be assembled into VLPs, in
contrast to attenuated virus, which must remain infectious.
VLPs are also safer as vaccines than infectious attenuated or
vector viruses for many populations since they do not contain a
genome. We have recently reported that a VLP vaccine candi-
date containing a stabilized pre-fusion F protein induces neu-
tralization titers, in both mice and cotton rats, at levels deemed
protective in humans.21,22
To assess the inﬂuence of previous RSV infections on the
efﬁcacy of our VLP vaccine candidates, we characterized
immune responses, in mice previously infected with RSV, to
VLPs containing a stabilized pre-fusion F protein or a stabilized
post-fusion F protein, contrasting results with a second RSV
infection. We report that in these RSV-experienced mice a sin-
gle injection of a pre-fusion F-containing VLP stimulates
extremely high titers of neutralizing antibodies while a single
injection of a post-fusion F-containing VLP or a second RSV
infection only weakly stimulates neutralizing antibodies. We
also found that the conformation of the F protein in VLPs
impacts the generation of anti-G protein IgG. The combined
results suggest that the conformation of the F protein is an
important consideration in RSV vaccine development.
Results
Characterization of protein content of VLP stocks
VLPs, based on Newcastle disease virus (NDV) core proteins
and containing the RSV G protein and either the pre-fusion or
post-fusion forms of the RSV F protein, were generated by
transfection of ELL-0 cells with plasmids encoding NDV M
protein, NDV NP, the H/G chimera protein,19 and either the
Pre-F/F or the Post-F/F chimera proteins to generate stocks of
VLP-H/GCPre-F/F or VLP-H/GCPost-F/F21. The protein con-
tent of the 2 puriﬁed VLP preparations was quantiﬁed by West-
ern blots and antibody binding to the puriﬁed VLPs. Fig. 1,
panel A, shows a Western blot of proteins in the 2 VLP prepa-
rations probed with anti-RSV F (lanes 1 and 2) or anti-RSV G
antibodies (lane 3 and 4). The results show that stocks of the 2
VLPs had equivalent levels of Pre-F/F and Post-F/F chimera
proteins and equivalent levels of the H/G chimera protein. The
2 F protein chimeras are different sizes since the Pre-F/F con-
tains the inserted foldon sequence and the Post-F/F chimera
has a deletion of 9 amino acids. The H/G chimera protein
resolves into heterogeneous species due to inefﬁcient glycosyla-
tion of the RSV G protein sequences as we have described pre-
viously.19,21 To further verify protein concentrations in VLPs, a
monoclonal antibody that will bind either form of the RSV F
protein, motavizumab,13,23 binds equally to the 2 VLPs (Fig. 1,
panel B) verifying that the 2 VLPs have assembled equivalent
levels of F protein. However, a monoclonal antibody speciﬁc
for site f present only in the pre-fusion form of F protein but
not in the post fusion form 14 binds only VLP-H/GCPre-F/F
and not VLP-H/GCPost-F/F (Fig. 1, panel C), a result verifying
the conformation of the pre-F protein and the post-F protein in
the 2 VLPs. A polyclonal antibody raised against a G protein
derived peptide bound equivalently to 2 different concentra-
tions of the 2 VLPs (Fig. 1, panel D) verifying that the 2 VLPs
have the same amount of H/G chimera protein.
Infection and immunization
To assess the generation of neutralizing antibody responses in
mice previously infected with RSV, 3 groups of 5 mice were
prepared by infection with RSV by intranasal inoculation. After
95 days, one group was immunized with VLP-H/GCPre-F/F,
another group immunized with VLP-H/GCPost-F/F, and a
third group was infected a second time with RSV (Fig. 2, top).
To directly compare responses in previously infected mice with
those in na€ıve mice, in parallel, groups of 5 na€ıve mice were
immunized in a prime (day 0) and a boost (day 100) with the
VLP-H/GCPre-F/F, with the VLP-H/GCPost-F/F, or RSV
infection (Fig. 2, bottom). Serum samples were obtained from
each mouse at different times starting at day 0.
Neutralization titers in previously infected and na€ıve
animals
To determine the effect of previous RSV infection on genera-
tion of neutralizing antibodies (NA), the neutralization titers in
pooled sera of mice at different times after an RSV prime and
VLP immunization were determined using an in vitro plaque
reduction assay (Fig. 3, panel A). A single injection of these
RSV-experienced animals with VLP-H/GCPre-F/Fs stimulated
signiﬁcantly higher NA titers than VLP-H/GCPost-F/Fs or a
second RSV infection. VLP-H/GCPre-F/F immunization
resulted in titers of approximately 4000 by day 128 while VLP-
H/GCPost-F/Fs stimulated NA titers of approximately 600 at
day 128, only slightly higher than a second RSV infection.
Fig. 3, panel B, illustrates, in parallel groups of na€ıve mice,
the neutralization titers in animals after a prime and after a
boost with the either VLP-H/GCPre-F/Fs, VLP-H/GCPost-F/
Fs, or after one or 2 RSV infections. These results are very simi-
lar to results previously reported for VLP immunization of
na€ıve animals.21 In a prime immunization, the VLP-H/GCPre-
F/Fs stimulated signiﬁcantly higher titers than the VLP-H/
GCPost-F/Fs or a single RSV infection. A boost with VLP-H/
GCPre-F/Fs increased titers to approximately 4000 while a
VLP-H/GCPost-F/Fs boost resulted in titers of approximately
2500. Two consecutive RSV infections produced NA titers of
approximately 200.
Total anti-F IgG titers after immunization of
RSV-experienced animals
To determine if the differences in the NA titers after a single
immunization of RSV-experienced mice with VLP-H/GCPre-
F/Fs or VLP-H/GCPost-F/Fs could be accounted for by differ-
ences in total anti-F protein antibody, the amounts of total
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anti-F protein IgG in the sera of the 2 groups were determined
at each time point and compared with IgG levels in RSV
infected mice. The titers of anti-F protein IgG that bind to
the soluble pre-fusion F protein are shown in Fig. 4, panels A,
while the binding of serum IgG to the soluble post-fusion F
protein is shown in panel B. The results show that a single
immunization with VLP-H/GCPre-F/Fs or VLP-H/GCPost-F/
Fs stimulated virtually equivalent titers of IgG speciﬁc for solu-
ble pre-fusion F protein or soluble post-fusion F protein. A sec-
ond RSV infection did stimulate anti-F protein IgG but the
levels were 10-fold lower than those stimulated by both VLPs.
Thus different levels of total anti-F protein IgG cannot account
for the differences in NA titers after immunization with the
VLP-H/GCPre-F/Fs or VLP-H/GCPost-F/Fs.
The IgG levels speciﬁc for pre-F and post-F targets gener-
ated in na€ıve mice after a prime VLP immunization and after a
boost immunization are shown in Fig. 4, panels C and D,
respectively. As previously reported,21 levels of IgG speciﬁc to
Figure 1. Protein content of VLPs. Panel A shows a Western blot of proteins present in stocks of VLP-H/GCPre-F/F and VLP-H/GCPost-F/F. Proteins (electrophesed in the
presence of reducing agent) in a polyacrylamide gel containing duplicate lanes of the proteins in the 2 VLPs were transferred to a membrane. One half was incubated
with anti-F antibody (lanes M, 1, 2). The other half was incubated with anti-G antibody (lanes 3, 4). M: marker Pre-F/F protein. Lanes 1, 3: VLP-H/GCPre-F/F; Lanes 2,
4: VLP-H/GCPost-F/F. The panel shows results of one of 3 separate blots with identical results. Panels B and C show binding of different concentrations of mAb motivizu-
mab (panel B) or mAb D25 (Panel C) to each VLP in an ELISA as described previously.21 Panel D shows binding of an anti-G protein peptide antibody to 2 different concen-
trations of VLPs (concentrations in ng of F protein). Results were identical in 3 or 4 separate determinations.
Figure 2. Immunization/infection timelines. Top panel shows timing of infection of
animals with RSV (day 0) and their subsequent immunization with VLPs (day 95) or
a second RSV infection (day 95). Sera were harvested from each animal at times
indicated by arrows pointing upwards. Bottom panel shows timing of prime immu-
nization with VLPs or RSV infection of na€ıve animals (day 0) and the subsequent
boost with VLPs or a second RSV infection (day 100). Sera were harvested at times
indicated by arrows pointing upward.
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the pre-F target are lower than those speciﬁc to the post-F tar-
get after immunization with either VLP. Interestingly, the levels
of IgG speciﬁc to both pre-F and post-F targets after a prime
and boost are approximately 10-fold lower than levels gener-
ated after RSV priming and a single VLP immunization
Total anti-G protein IgG titers after immunization
of RSV-experienced or na€ıve animals
Antibodies speciﬁc for the RSV G protein also have a role
in protective responses to RSV infection.24-27 Thus it was of
interest to determine the inﬂuence of previous RSV infec-
tion on generation of anti-G protein antibodies. The titers
of anti-G protein IgG antibodies in the parallel sets of na€ıve
and RSV-experienced mice were determined using soluble
G protein as target in ELISA. Fig. 5, panel A, shows anti-
body titers in sera after VLP-H/GCPre-F/F or VLP-H/
GCPost-F/F immunization of RSV-experienced mice while
panel B shows titers after a prime and a boost of na€ıve
mice with VLP-H/GCPre-F/Fs or VLP-H/GCPost-F/Fs or
RSV. In both na€ıve and RSV-experienced mice, anti-G pro-
tein antibody levels were extremely low after a single RSV
infection or after a single VLP immunization. A second
RSV infection in both sets of mice only minimally stimu-
lated anti-G protein antibody levels. In contrast, VLP prime
and boost immunization of na€ıve mice substantially
increased anti-G protein antibody titers. Importantly, in
RSV-experienced animals, a single VLP immunization with
either the VLP-H/GCPre-F/F or the VLP-H/GCPost-F/F
considerably increased the anti-G protein antibody titers
and this increase was approximately 4-fold over that stimu-
lated by a prime and boost with either VLP in na€ıve
animals.
A surprising result was that the levels of anti-G protein anti-
bodies after a single VLP immunization of RSV-experienced
animals or after a VLP prime and boost of na€ıve animals were
signiﬁcantly different depending upon the VLP used although
both VLPs contained similar amounts of the same H/G protein
(Fig. 1, panels A and D).21 VLPs containing the pre-fusion F
protein simulated signiﬁcantly higher titers of anti-G protein
antibody than the VLPs containing the post-F protein.
Protection from RSV challenge
To determine if a single VLP immunization of RSV-experi-
enced animals could protect them from RSV replication in
lungs after RSV challenge, mice were challenged with RSV
125 d after VLP immunization. Fig. 6 shows titers of virus
in lung homogenates. While good titers were obtained in
the unprimed, unimmunized controls (lane A), no virus
was detected at the limits of detection in lungs of immu-
nized animals. The results demonstrated that immunization
with either VLP of RSV primed animals protected them
from RSV replication.
Results of the challenge of na€ıve, immunized mice have been
previously published.21
Figure 3. Neutralization titers in sera from RSV-experienced or na€ıve animals. Panel A shows neutralization titers in pooled sera after a single immunization with VLPs of
RSV previously infected animals. At day 128, the difference between results of VLP-H/GCPre-F/F immunization and VLP-H/GCPost-F/F immunization was signiﬁcant with
a p value of 0.0009. The difference between VLP-H/GCPre-F/F and RSV immunization was signiﬁcant with a p value of 0.0005. Difference between VLP-H/GCPost-F/F
and RSV immunization was not signiﬁcant. All results are the average of 4 separate determinations with mean and standard deviation shown. Panel B shows neutraliza-
tion titers in pooled sera after a prime and after a boost of na€ıve animals with VLPs or RSV. At day 71, p values for the difference between results of immunization with
VLP-H/GCPre-F/F and VLP-H/GCPost-F/F was 0.0005 and for the difference between VLP-H/GCPre-F/F and RSV was 0.0030. The difference between VLP-H/GCPost-F/F
and RSV was not signiﬁcant. At day 128, the difference between results of VLP-H/GCPre-F/F immunization and VLP-H/GCPost-F/F immunization was not signiﬁcant. The
p values for difference between VLP-H/GCPre-F/F and RSV immunization was 0.035 and for the difference between VLP-H/GCPost-F/F and RSV immunization was
0.0012. Results are the average of 3 separate determinations with mean and standard deviation shown.
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Figure 4. Total anti-F protein antibody in animal sera. Total anti-F protein antibody was measured in ELISA using as target puriﬁed soluble pre-fusion F (panels A and C) or
puriﬁed soluble post-fusion F protein (panels B and D). Panels A and B show ng/ml of anti-F protein IgG at different time points in RSV-experienced animals. Results are
the average of 2 separate determinations. For the pre-F target as well as post-F target the difference at day 128 between RSV/VLP-H/GCPre-F/F and RSV/VLP-H/GCPost-
F/F groups was not signiﬁcant. For the pre-F target, p value for difference between RSV/VLP-H/GCPre-F/F and RSV/RSV was 0.030 while the difference between RSV/RSV
and RSV/VLP-H/GCPost-F/F immunization was not signiﬁcant. For the post F target, the p values for differences between RSV/VLP-H/GCPre-F/F or RSV/VLP-H/GCPost-F/
F VLP immunization and RSV/RSV immunization were 0.034 and 0.0011, respectively. Panels C and D show ng/ml of anti-F protein IgG at different time-points in immu-
nized na€ıve animals. Figure shows results of one of 2 determinations with identical results and replicates results previously reported.21 For the pre-F target or the post-F
target the differences in values at day 128 between all groups were not signiﬁcant.
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Discussion
Most people have been infected with RSV by 5 y of age,17 but
these infections do not generate robust protective immune
responses as many individuals experience repeated RSV infec-
tions throughout life, infections that have not been attributed
to different strains or antigenic variants.7,16,28 However, these
infections likely result in some level of pre-existing immunity
that could impact the effectiveness of any vaccine. Thus a suc-
cessful vaccine candidate targeted to adult populations or older
children must generate protective responses in the context of
any pre-existing immunity.
We have developed VLP vaccine candidates for RSV.18 Our
previous studies have demonstrated that VLPs containing the
pre-fusion form of the RSV F protein stimulate high titers of
NA in both na€ıve mice and cotton rats, in contrast to RSV
infection.21,22 The goal of the studies reported here was to
mimic human populations by assessing immune responses to
our VLP vaccine candidates in mice previously infected with
RSV.
When comparing NA titers, we found that in animals
previously infected with RSV, a single immunization with
VLP-H/GCPre-F/Fs stimulated signiﬁcantly higher NA
titers than a single immunization with VLP-H/GCPost-F/Fs
or a second RSV infection. The NA titers after a single
VLP-H/GCPre-F/F immunization of previously infected
mice were comparable to titers in sera of na€ıve mice only
after both a prime and a boost with VLP-H/GCPre-F/Fs.
Figure 5. Total anti-G protein antibody in animal sera. Total anti-G protein IgG was measured in ELISA using as target soluble G protein. Panel A shows ng/ml of anti-G
protein IgG at different times in RSV-experienced animals. The results are the average of 4 separate determinations with average and standard deviations shown.
At day128, p value for the difference between RSV/VLP-H/GCPre-F/F and RSV/VLP-H/GCPost-F/F immunization was 0.0057, the p value for the difference between RSV/
VLP-H/GCPost-F/F and RSV/RSV was 0.002. The p value for the difference between RSV/VLP-H/GCPre-F/F and RSV/RSV was 0.0002. Panel B shows ng/ml of anti-G protein
IgG in immunized na€ıve animals. Results are the average of 2 separate determinations with standard deviations shown. At day 128, p values for differences between
VLP-H/GCPre-F/F and VLP-H/GCPost-F/F immunization, for RSV and VLP-H/GCPre-F/F-VLP immunization, and for RSV and VLP-H/GCPost-F/F immunization were 0.042,
0.019, and 0.055 respectively.
Figure 6. Protection from challenge. Shown are lung titers after challenge of RSV-
experienced VLP immunized animals. RSV challenge was 125 d after VLP immuni-
zation. A: no RSV prime, no immunization; B: RSV primed, RSV immunized; C: RSV
primed, VLP-H-GCPre-F/F immunized; D: RSV primed, VLP-H/GCPost-F/F immu-
nized. Each group contained 5 animals and titers of each animal are shown in the
graph. The p value for the differences between group A and the other groups is
0.0182.
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This result suggests the hypothesis that RSV infection does
induce potent neutralizing antibody memory responses that
can be activated by the VLP-H/GCPre-F/F immunization
but not by VLP-H/GCPost-F/Fs or a second RSV infection.
A recent paper from Gilman, et al29 supports the idea
that RSV infection induces pre-F memory cells. These
investigators report the isolation and characterization of
364 F protein speciﬁc monoclonal antibodies (mAbs) from
memory B cells in serum of 3 human donors, donors who
were infected with RSV in the past. The main conclusions
of this comprehensive study are that most of the antibodies
target one of 6 deﬁned antibody-binding sites on the F pro-
tein. Importantly, approximately 50% of the mAbs were
speciﬁc to one of the 3 sites present only on the pre-fusion
F protein, sites f, III, and V, and these mAbs were potent
virus neutralizers. The vast majority of the rest of the anti-
bodies bound sites common to both the pre-fusion and
post-fusion F proteins but, in general, were far less potent
neutralizers requiring 10-fold or higher concentrations to
neutralize than those mAbs that bound to sites unique to
the pre-fusion F protein. These poorly neutralizing antibod-
ies bound primarily to sites I, II, and IV. These ﬁndings
show that RSV infection does indeed induce signiﬁcant lev-
els of memory B cells that encode high titer neutralizing
antibodies, at least in humans. Our results suggest that RSV
infection can induce protective memory in mice but a sub-
sequent infection cannot activate these memory B cells.
In contrast to results with VLP-H/GCPre-F/Fs, a single
immunization with VLP-H/GCPost-F/F in RSV infected mice
resulted in NA titers more similar to those observed after a sin-
gle VLP-H/GCPost-F/F immunization of na€ıve mice. However,
a prime/boost immunization of na€ıve mice with VLP-H/
GCPost-F/Fs stimulated good NA titers, titers that were
approximately 50% that simulated by VLP-H/GCPre-F/Fs.
That the VLP-H/GCPost-F/F immunization in RSV-experi-
enced mice did not stimulate these higher NA titers suggests
that the RSV infection may not induce memory responses to
some determinants present in the VLP-H/GCPost-F/Fs pre-
venting high NA titers with a single VLP-H/GCPost-F/F
immunization.
While it was possible that differences in NA titers after VLP-
H/GCPre-F/F or VLP-H/GCPost-F/F immunization of
RSV-experienced mice were due to differences in total levels of
anti-F protein antibodies in sera of the animals, our data clearly
demonstrated that the levels of total anti-F protein antibodies
in animals immunized with VLP-H/GCPre-F/Fs were virtually
identical to levels of total antibodies in VLP-H/GCPost-F/F
immunized animals. Thus the differences in NA titers in the
VLP-H/GCPre-F/F and VLP-H/GCPost-F/F immunized,
RSV-experienced animals must be due to qualitative differences
between the populations of anti-F protein antibodies in the 2
groups of animals. Immunization of RSV-experienced mice
with either VLP did result in much higher anti-F protein anti-
body titers than a second RSV infection indicating that a sec-
ond RSV infection very poorly activates secondary antibody
responses in contrast to the VLP immunization. It is notewor-
thy that na€ıve mice have total IgG anti-F protein levels after a
prime and boost with VLPs similar to that observed after RSV
infection. However, total antibody levels by day 128 in these
na€ıve mice were approximately 10-fold lower than total levels
in the VLP immunized RSV-experienced mice. The reasons for
this difference are a topic of future investigations.
Studies of protective immune responses to RSV have largely
focused on the role of the F protein. Indeed, the most broadly
neutralizing antibodies are speciﬁc to the F protein since the G
protein sequence varies with the serotype of RSV, in contrast to
the F protein.30 Furthermore, anti-G protein antibody
responses are generally poorly neutralizing, a conclusion we
conﬁrmed by assessing neutralizing antibody responses in mice
immunized with VLPs containing only the G protein.19 How-
ever, antibodies to G protein do have a role in protection from
RSV induced disease. The G protein central region contains a
conserved sequence that is a mimic of the chemokine CX3C
(fractalkine).27 The G protein competes for the binding of
CX3C to its receptor, CX3CR1, inhibiting immune responses
to RSV in several ways that enhance the pathology of the infec-
tion27,31,26 Antibodies to the G protein CX3C sequence block G
protein binding to the CX3CR1 moderating RSV disease.
Importantly, antibody to this CX3C sequence decrease
enhanced respiratory disease that results from RSV challenge
of FI-RSV vaccinated animals.32 Treatment with mAb to CX3C
sequence decreased symptoms in RSV infected mice.25 For
these reasons, we compared levels of total anti-G protein IgG
in na€ıve mice immunized with VLPs or infected with RSV to
levels of these antibodies in RSV-experienced mice after VLPs
immunization or a second RSV infection. Results show that in
na€ıve mice a single RSV infection or one VLP immunization
(prime) both generate anti-G protein antibodies very poorly.
However, a single immunization with either VLP in RSV-expe-
rienced animals resulted in signiﬁcant titers of anti-G protein
antibodies suggesting that RSV infection does induce memory
responses to the G protein. In contrast, a second infection with
RSV results in barely detectable levels of anti-G protein anti-
body suggesting that RSV cannot effectively stimulate this anti-
G protein memory. One surprising result of this analysis is that
the VLP-H/GCPre-F/F induced signiﬁcantly higher titers of
anti-G protein IgG than the VLP-H/GCPost-F/F in both na€ıve
and RSV-experienced animals. It is important to point out that
the 2 different VLPs, VLP-H/GCPre-F/Fs and VLP-H/
GCPost-F/Fs, contain the same H/G chimera protein and in
the same amounts.21 These results suggest that the conforma-
tion of the F protein in VLPs inﬂuences induction and stimula-
tion of total anti-G IgG.
In summary, results of assessing levels of anti-F or anti-G
protein antibodies in RSV-experienced animals vs na€ıve ani-
mals suggests the hypothesis that RSV infection can induce
memory responses but infection is defective in stimulating or
activating that memory. Further, these results indicate that the
conformation of the F protein in a vaccine candidate has signif-
icant impact on the nature of anti-RSV immune responses in
mice previously infected with RSV.
Materials and methods
Cells, virus, plasmids
ELL-0 (avian ﬁbroblasts) (CLR-12203), Vero cells (CLR-1586),
COS-7 cells (CLR-1651), and Hep2 cells (CCL-23) were
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obtained from the American Type Culture Collection.
Expi293F cells were obtained from ThermoFisher/Invitrogen
(A14527). ELL-0 cells, Vero cells, COS-7 cells, and Hep2 cells
were grown in DMEM (Invitrogen 1195–073) supplemented
with penicillin, streptomycin (Invitrogen 15140–122), and 5%
(Vero cells) or 10% fetal calf serum (Invitrogen 10437–028).
Expi293F cells were grown in Expi293 media (ThermoFisher/
Gibco/Invitrogen A1435101). RSV, A2 strain, was obtained
from Dr. Robert Finberg.
VLPs containing the RSV F and G proteins are formed with
the Newcastle disease virus (NDV) core proteins NP and
M.18,33 The cDNAs encoding the NDV NP and M protein have
been described previously.34 The RSV F and G proteins are
incorporated into these VLPs by constructing chimera protein
genes composed of ectodomains of the G or F glycoproteins
fused to the transmembrane (TM) and cytoplasmic (CT)
domains of the NDV HN protein or NDV F glycoprotein,
respectively. These NDV domains speciﬁcally interact with the
NDV NP and M protein resulting in efﬁcient incorporation of
the chimera proteins into VLPs.
The construction, expression, and incorporation of the chi-
mera protein NDVHN/ RSVG (H/G) into VLPs have been
described previously.19 The construction, expression, and
incorporation into VLPs of the stabilized pre-fusion F protein
(Pre-F/F DS-Cav1) to generate VLP-H/GCPre-F/F, and the
stabilized post-fusion F protein (Post-F/F) to create VLP-H/
GCPost-F/F have been described previously.21
The construction of genes encoding the soluble pre-F pro-
tein, the soluble post-F protein, and the soluble G protein used
for target in ELISA was described previously.21
Polyacrylamide gel electrophoresis, silver staining,
and western analysis
Proteins were resolved on 8% Bis-Tris gels (NuPage, Thermo-
Fisher/Invitrogen WB1001/WG1002)). Silver staining of pro-
teins in the polyacrylamide gels was accomplished as
recommended by the manufacturer (ThermoFisher/Pierce
24600). Quantiﬁcation of NP, M, different forms of F/F, H/G
protein, and soluble pre-F, post-F, and soluble G was accom-
plished after their separation in polyacrylamide gels followed
by silver staining or by Western blots of the proteins as well as
protein standards as described previously.35,36 For Western
analysis, proteins in the polyacrylamide gels were transferred to
PVDF membranes using dry transfer (iblot, ThermoFisher/
Invitrogen iB401001). Proteins were detected in the blots using
anti-RSV HR2 peptide antibody or anti-RSV antibody.
Antibodies
RSV F monoclonal antibody clone 131–2A (Millipore
MAB8599) was used in RSV plaque assays. Monoclonal anti-
body (mAb) 1112, mAb 1200, mAb 1243, were generous gifts
of Dr. J. Beeler37 and used to verify F protein conformations,
and mAb D25 and mAb motavizumab, generous gifts of Dr. J.
McLellan,,14 were used for ELISA analysis of VLPs and soluble
F proteins. Anti-RSV F protein HR2 antibody used for Western
Blots is a polyclonal antibody speciﬁc to the HR2 domain of
the RSV F protein.18 Anti-RSV G protein antibody is a
polyclonal antibody raised against a peptide containing G pro-
tein amino acids 180–198 (ThermoFisher PA5–22827). Second-
ary antibodies against goat (A5420), mouse (A5906) and rabbit
IgG (A0545) were purchased from Sigma.
VLP preparation, puriﬁcation, and characterization
For preparations of VLPs to be used as immunogens (VLP-H/
GCPre-F/F, VLP-H/GCPost-F/F), ELL-0 cells growing in
T-150 ﬂasks were transfected with cDNAs encoding the NDV
M protein, NP, the chimeric proteins H/G, and either Pre-F/F or
Post-F/F as described previously.18,19 At 24 hours post-transfection,
heparin (Sigma, H4784) was added to the cells at a ﬁnal concentra-
tion of 10mg/ml19 to inhibit rebinding of released VLPs to cells. At
72, 96, and 120 hours post-transfection, cell supernatants were col-
lected and VLPs puriﬁed by sequential pelleting and sucrose gradi-
ent fractionation as described previously.18,19,35 Concentrations of
proteins in the puriﬁed VLPs were determined by silver-stained
polyacrylamide gels and byWestern analysis usingmarker proteins
for standard curves.18,35 The conformation of F protein in the VLP
preparations was veriﬁed by reactivity tomAbs.
Preparation of soluble F proteins
Expi293F cells were transfected with pCAGGS vector contain-
ing sequences encoding the soluble pre-F protein or the soluble
post-F protein. At 5 to 6 d post transfection, total cell superna-
tants were collected and cell debris removed by centrifugation.
Pre-fusion and post-fusion polypeptides were then puriﬁed on
columns using the His tag and then the strep tag as described
previously.15
Quantiﬁcation of soluble F protein and VLP associated F
protein
Determinations of amounts of RSV F protein in VLPs or in sol-
uble F protein preparations were accomplished by Western
blots using anti-HR2 antibody for detection and comparing the
signals obtained with a standard curve of puriﬁed F proteins as
described previously.35 Quantiﬁcation of amounts of soluble G
protein was determined on Western blots using anti-RSV G
protein antibody for detection.
Preparation of RSV, RSV plaque assays, and antibody
neutralization
RSV was grown in Hep2 cells,18,19 and RSV plaque assays were
accomplished on Vero cells as described previously.21 Antibody
neutralization assays in a plaque reduction assay have been
described previously.21,22 Neutralization titer was deﬁned as the
reciprocal of the dilution of serum that reduced virus titer by 50%.
Animals, animal immunization, and RSV challenge
Mice, 4-week-old female BALB/c, from Taconic laboratories
(BALB-F), were housed (groups of 5) under pathogen-free con-
ditions in microisolator cages at the University of Massachu-
setts Medical Center animal quarters. Female mice were used
to assess the potential of VLPs for maternal immunization. Pro-
tocols requiring open cages were accomplished in biosafety
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cabinets. BALB/c mice were immunized by intramuscular (IM)
inoculation of 30 mg total VLP protein (5 mg F protein) in
0.05 ml of TNE (50 mM Tris-HCl, pH 7.4, 150 mM NaCl,
5 mM EDTA) containing 10% sucrose. For infections with
RSV, the animals were lightly anesthetized with isoﬂurane and
then infected by intranasal (IN) inoculation of 50 ml of RSV (1
£ 107 pfu/ml). All animal procedures and infections were per-
formed in accordance with the University of Massachusetts
Medical School IACUC and IBC approved protocols.
ELISA protocols
For determination of anti-F protein or anti-G protein serum
antibody titers, blood was obtained from immunized animals
by tail vein nicks and centrifuged in BD microtainer serum sep-
arator tubes (ThermoFisher 365967) to remove blood cells. For
ELISA, wells of microtiter plates (ThermoFisher/Costar 2797)
were coated with either puriﬁed soluble pre-fusion F protein,
soluble post-fusion F protein, or soluble G protein and incu-
bated for 24 hours at 4C. Wells were then incubated in PBS-
2% BSA for 16 hours. Different dilutions of sera, in 0.05%
Tween and 2% BSA, were added to each well and incubated for
2 hours at room temperature. After 6 washes in PBS, sheep
anti-mouse antibody coupled to HRP (Sigma A5906) was
added in 50 ml PBS-2%BSA and incubated for 1.5 hours at
room temperature. Bound HRP was detected by adding 50 ml
TMB (3,305,50-tetramethylbenzidin, ThermoFisher34028) and
incubating for 5–20 minutes at room temperature until blue
color developed. The reaction was stopped with 50ml 2N sulfu-
ric acid. Color was read in SpectraMax Plus Plate Reader
(Molecular Devices) using SoftMax Pro software. Amounts of
IgG bound to the wells was calculated using a standard curve
generated using deﬁned amounts of puriﬁed IgG.35
Statistical analysis
Statistical analyses (student T test) of data were accomplished
using Graph Pad Prism 6 software.
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